IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 278 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $265,816 | +120178.7% | 37,758 | +3.8% | 0.00% | 0.0% |
| Q1 2023 | $221 | +0.9% | 36,373 | +5.8% | 0.00% | 0.0% |
| Q4 2022 | $219 | -99.9% | 34,373 | +11.3% | 0.00% | -50.0% |
| Q3 2022 | $295,000 | -15.0% | 30,873 | -2.2% | 0.00% | 0.0% |
| Q2 2022 | $347,000 | -8.0% | 31,555 | +39.1% | 0.00% | 0.0% |
| Q1 2022 | $377,000 | -13.9% | 22,684 | -1.3% | 0.00% | 0.0% |
| Q4 2021 | $438,000 | +5375.0% | 22,992 | +6469.1% | 0.00% | – |
| Q3 2021 | $8,000 | -38.5% | 350 | -30.0% | 0.00% | – |
| Q2 2021 | $13,000 | -13.3% | 500 | 0.0% | 0.00% | – |
| Q1 2021 | $15,000 | -34.8% | 500 | 0.0% | 0.00% | – |
| Q4 2020 | $23,000 | -23.3% | 500 | -45.2% | 0.00% | – |
| Q3 2020 | $30,000 | +25.0% | 912 | +5.7% | 0.00% | – |
| Q2 2020 | $24,000 | -14.3% | 863 | -7.2% | 0.00% | – |
| Q1 2020 | $28,000 | +33.3% | 930 | +24.0% | 0.00% | – |
| Q4 2019 | $21,000 | +2000.0% | 750 | +814.6% | 0.00% | – |
| Q1 2019 | $1,000 | – | 82 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |